...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study.
【24h】

Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study.

机译：Vinorelbine顺铂的组合预防患者晚期非小细胞肺癌taxane-based进行预处理养生法:一项多中心II期研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To assess the efficacy and tolerance of the vinorelbine/cisplatin combination in non-small cell lung cancer patients pre-treated with a taxane-based regimen. PATIENTS AND METHODS: Among the 32 enrolled patients, 28 (87.5%) had a PS (WHO) of 0-1 and 13 (40.6%) have previously received both platinum compounds and taxanes. Vinorelbine (25 mg/m2 on days 1 and 8) was given by a rapid i.v. infusion and cisplatin (80 mg/m2 on day 8) after appropriate hydration. The treatment was repeated every 3 weeks. RESULTS: A partial response was achieved in six patients (ORR=18.8%; 95% confidence interval: 5.23-32.27); 13 (44.8%) and 10 (34.5%) patients had stable and progressive disease, respectively (intention-to-treat analysis). Four partial responses were observed in patients who were previously treated with taxanes/platinum-containing regimens. The median time to tumor progression was 4.7 months (range, 1.3-15.4). After a median follow-up period of 6.3 months (range, 1.3-15.4) the median overall survival was 7.6 months and the 1-year survival rate 17.7%. Grade 3 and 4 granulocytopenia was observed in 11 (34.4%) patients and grade 4 thrombocytopenia in one (3.1%). Eleven (34.4%) patients presented grade 2 and 3 anemia. Febrile neutropenia occurred in one (3.1%) patient. Grade 3 and 4 nausea/vomiting was reported in one (9.3%) patient each and grade 2 fatigue in four (12.5%). CONCLUSIONS: The combination of vinorelbine and cisplatin is an active and well tolerated salvage regimen in NSCLC patients pre-treated with taxane-based chemotherapy.
机译：目的:评估的有效性和宽容vinorelbine /顺铂联合非小细胞肺癌患者预处理taxane-based方案。方法:在32了病人,28(87.5%)的PS(世卫组织)0 - 1和13例(40.6%)铂化合物和之前收到紫杉烷。是由一个快速灌注顺铂静脉输液吗(80 mg / m2 8天)后适当的水合作用。每3周进行重复治疗。结果:部分反应是取得了六个患者(奥尔= 18.8%;5.23 - -32.27);有稳定和进步的疾病,分别(意向处理分析)。在患者反应观察以前对待紫杉烷/ platinum-containing方案。肿瘤进展时间为4.7个月(范围,1.3 - -15.4)。个月(范围1.3 - -15.4)总体中位数生存期是7.6个月和1年期的生存率17.7%。观察11例(34.4%)患者和4级血小板减少症(3.1%)。例2和3年级贫血。嗜中性白血球减少症发生在一个病人(3.1%)。3和4恶心/呕吐被报道(9.3%)患者和2级疲劳在四个(12.5%)。vinorelbine,顺铂是一个活跃的容忍NSCLC患者的救助方案预处理与taxane-based化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号